Stockscreener 앱 받기
14.07
1.37%
0.19
시간 외 거래:
14.20
0.13
+0.92%
전일 마감가:
$13.88
열려 있는:
$13.99
하루 거래량:
5.96M
Relative Volume:
1.29
시가총액:
$10.92B
수익:
$220.00K
순이익/손실:
$-1.21B
주가수익비율:
-8.7724
EPS:
-1.6039
순현금흐름:
$-387.48M
1주 성능:
+7.82%
1개월 성능:
-16.60%
6개월 성능:
-17.28%
1년 성능:
-29.12%
1일 변동 폭
$13.83
$14.50
1주일 범위
$12.92
$14.58
52주 변동 폭
$12.55
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
14.07 | 10.97B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-08 | 개시 | Stifel | Buy |
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Why is SMMT stock tumbling today? - MSN
Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through It (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Inc. (SMMT) Investor Outlook: Evaluating A Potential 103.85% Upside - DirectorsTalk Interviews
SMMT Jumps As Summit Therapeutics Rides Ivonescimab Momentum - timothysykes.com
Summit rebounds after nearly $50M insider purchase - MSN
Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering - Insider Monkey
Insider Buying: Summit Therapeutics Co-CEO, President & Director Bought US$1.5m Of Shares - simplywall.st
Summit Therapeutics files for $500M common stock offering; shares slide over 9% - MSN
Summit Therapeutics (SMMT) Shares Rebound After Co-CEO's $50M St - GuruFocus
5 Best Buy-the-Dip Stocks to Invest In Now - Insider Monkey
SMMT Jumps As Ivonescimab Trial Success Fuels Financing Drive - StocksToTrade
Summit Therapeutics (NASDAQ: SMMT) investors approve directors and 8M-share incentive plan boost - Stock Titan
Summit Therapeutics co-CEO Zanganeh acquires $49.98m in shares By Investing.com - Investing.com Australia
Summit Therapeutics(SMMT.US) 10% Shareholder Buys US$49.99 Million in Common Stock - Moomoo
Insider Stock Purchases: June 12, 2026 - Quiver Quantitative
Summit Therapeutics co-CEO Zanganeh acquires $49.98m in shares - Investing.com
Co-CEO Mahkam Zanganeh (SMMT) reports spouse’s 3.81M-share open-market buy - Stock Titan
Summit Therapeutics (SMMT) Shares Rebound After Co-CEO's $50M Stock Purchase - GuruFocus
Summit gains after nearly $50M insider buy (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics stock rises after CEO share purchase By Investing.com - Investing.com Canada
Summit Therapeutics stock rises after CEO share purchase - Investing.com
Summit Therapeutics Insider Bought Shares Worth $49,987,200, According to a Recent SEC Filing - Moomoo
Summit Therapeutics co-CEO Robert Duggan buys $49.9m in stock - Investing.com India
Summit Therapeutics co-CEO Robert Duggan acquires 3.81 million shares - StreetInsider
Summit Therapeutics Co-Chief Executive Officer Purchased Shares Worth Over $49M - TradingView
Summit Therapeutics (SMMT) Co-CEO Robert Duggan buys 3.81M shares in open market - Stock Titan
Summit Therapeutics Halts US$500m Offering After Ivonescimab Trial Results - Yahoo Finance
Summit Therapeutics (SMMT) Withdraws Public Offering Amid Market Conditions - GuruFocus
Summit Therapeutics (SMMT) Withdraws $500M Public Offering Amid Market Conditions - GuruFocus
Summit pulls $500M share sale a day after announcing it - BioPharma Dive
Summit Therapeutics withdraws proposed securities offering citing market conditions - MSN
Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing - TradingView
Summit Therapeutics withdraws proposed underwritten offering citing market conditions - TradingView
Summit Therapeutics (NASDAQ: SMMT) pulls planned stock sale amid markets - Stock Titan
Summit Therapeutics stock hits 52-week low at 13.14 USD By Investing.com - Investing.com Nigeria
Summit Therapeutics (SMMT) Sees a 10.2% Decline - GuruFocus
Oil Jumps On Iran Strikes, Nasdaq 100 Falls On Hot Inflation: Stock Market Today - Benzinga
Summit Therapeutics stock hits 52-week low at 13.14 USD - Investing.com
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Summit Therapeutics Inc 주식 (SMMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 12 '26 |
Buy |
13.12 |
3,810,000 |
49,987,200 |
573,883,879 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Soni Manmeet Singh | COO and CFO |
Jun 04 '26 |
Buy |
14.45 |
50,000 |
722,250 |
3,123,603 |
| Xia Yu | Director |
Oct 21 '25 |
Buy |
18.74 |
533,617 |
9,999,983 |
32,057,147 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
2.60%
0.94%
자본화:
|
볼륨(24시간):